8.65

27.02% 1.84

After Hours: 8.51 -0.14 -1.62%

Alpha Cognition Inc (ACOG)

Overview News Price History Discussions Forecast

Alpha Cognition Inc stock is traded at $8.65, with a volume of 669.36K. It is up +27.02% in the last 24 hours and up +103.53% over the past month. Alpha Cognition Inc is a biopharmaceutical company dedicated to developing treatments for patients suffering from neurodegenerative diseases, such as Alzheimer's disease, for which there are limited or no treatment options. The Company's current focus is on the commercial manufacturing and sales of ZUNVEYL oral tablet formulation. The Company's commercial development program for ZUNVEYL is primarily focused on building a long-term care commercial team that can focus on providing key points of differentiation, exploiting key issues with existing Acetylcholinesterase inhibitors treatments, and seeking potential licensing partners for other additional indications and new formulations.

Previous Close:

$6.81

Open:

$7.15

24h Volume:

669.36K

Relative Volume:

8.71

Market Cap:

$138.57M

Revenue:

Net Income/Loss:

$-14.72M

P/E Ratio:

-3.0565

EPS:

-2.83

Net Cash Flow:

$-7.41M

1W Performance:

+16.42%

1M Performance:

+103.53%

6M Performance:

+61.09%

1Y Performance:

+0.00%

1-Day Range:

$6.95

$9.68

1-Week Range:

$6.55

$9.68

52-Week Range:

$3.75

$9.68

Alpha Cognition Inc Stock (ACOG) Company Profile

Name

Alpha Cognition Inc

Sector

Healthcare (1170)

Industry

Biotechnology (671)

Phone

(858) 344-4375

Address

1200-750 W PENDER ST, VANCOUVER

Employee

Twitter

Next Earnings Date

Latest SEC Filings

ACOG's Discussions on Twitter

Compare ACOG with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
ACOG Alpha Cognition Inc	8.65	119.03M	0	-14.72M	-7.41M	-2.83
ONC Beigene Ltd Adr	228.38	25.07B	3.81B	-644.79M	-669.77M	-6.24
VRTX Vertex Pharmaceuticals Inc	438.65	109.14B	11.10B	-988.90M	-1.26B	-3.92
AKTX Akari Therapeutics Plc Adr	1.27	36.39M	0	0	0	0.00
REGN Regeneron Pharmaceuticals Inc	594.32	56.98B	14.09B	4.50B	2.96B	39.28
VRNA Verona Pharma Plc Adr	71.31	5.39B	0	-153.72M	-103.81M	-2.00

Alpha Cognition Inc Stock (ACOG) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Mar-18-25	Initiated	H.C. Wainwright	Buy

Alpha Cognition Inc Stock (ACOG) Latest News

08:21 AM

We Think Alpha Cognition (NASDAQ:ACOG) Can Easily Afford To Drive Business Growth - Yahoo Finance

08:21 AM

12:00 PM

Alpha Cognition Inc. Reports First Quarter 2025 Financial Results and Operating Overview - BioSpace

May 15, 2025

May 11, 2025

Alpha Cognition (ACOG) Expected to Announce Earnings on Tuesday - Defense World

May 11, 2025

May 06, 2025

Alpha Cognition, Inc.’s (NASDAQ:ACOG) Lock-Up Period To Expire on May 12th - Defense World

May 06, 2025

May 02, 2025

Will Alpha Cognition's Recently Launched Alzheimer's Drug Be A Commercial Success? - RTTNews

May 02, 2025

May 01, 2025

Alpha Cognition to Report First Quarter 2025 Financial Results and Operating Overview - BioSpace

May 01, 2025

Apr 30, 2025

Alpha Cognition, Inc. Announces Participation in the D. Boral Capital Inaugural Global Conference - The Kingston Whig Standard

Apr 30, 2025

Apr 28, 2025

Alpha Cognition to Present ZUNVEYL® (Benzgalantamine) Clinical Data at 2025 Alzheimer’s Association International Conference - Yahoo Finance

Apr 28, 2025

(Benzgalantamine) Clinical Data at 2025 Alzheimer’s Association International Conference - Business Wire

Apr 28, 2025

Apr 14, 2025

Alpha Cognition Inc. Reports Strong 2024 Financials - TipRanks

Apr 14, 2025

Apr 11, 2025

Alpha Cognition Strengthens Its Leadership Team with Appointment of Robert Wills to Board of Directors and Announces Departure of Existing Director John Havens - BioSpace

Apr 11, 2025

Apr 10, 2025

Alpha Cognition announces board changes - Investing.com

Apr 10, 2025

Alpha Cognition announces board changes By Investing.com - Investing.com Canada

Apr 10, 2025

Alpha Cognition Appoints Robert Wills To Board - citybiz

Apr 10, 2025

Apr 09, 2025

Alpha Cognition Earnings Call: Positive Outlook Amid Growth - TipRanks

Apr 09, 2025

Apr 08, 2025

Alpha Cognition Announces a $44 Million Exclusive Licensing Agreement for the Development and Commercialization of ZUNVEYL (benzgalantamine), an FDA-Approved Treatment for Mild-to-Moderate Alzheimer’s Disease, in China - The Globe and Mail

Apr 08, 2025

Apr 05, 2025

Alpha Cognition stock hits 52-week low at $4.65 amid downturn - Investing.com Canada

Apr 05, 2025

Apr 04, 2025

HC Wainwright Expects Stronger Earnings for Alpha Cognition - Defense World

Apr 04, 2025

Apr 01, 2025

Stonegate Capital Partners Updates Coverage on Alpha Cognition Inc. (ACOG) Q4 2024 - TradingView

Apr 01, 2025

Alpha Cognition (NASDAQ:ACOG) Given Buy Rating at HC Wainwright - Defense World

Apr 01, 2025

Mar 31, 2025